-
1
-
-
84884933036
-
Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement
-
Dinner S, Witteles W, Afghahi A, Witteles R, Arai S, Lafayette R, et al. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica. 2013;98(10): 1593-9.
-
(2013)
Haematologica
, vol.98
, Issue.10
, pp. 1593-1599
-
-
Dinner, S.1
Witteles, W.2
Afghahi, A.3
Witteles, R.4
Arai, S.5
Lafayette, R.6
-
2
-
-
79955842001
-
Amyloidosis: Pathogenesis and new therapeutic options
-
Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):1924-33.
-
(2011)
J Clin Oncol
, vol.29
, Issue.14
, pp. 1924-1933
-
-
Merlini, G.1
Seldin, D.C.2
Gertz, M.A.3
-
3
-
-
80052286754
-
Cardiac amyloidosis: A treatable disease, often overlooked
-
Falk RH. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation. 2011;124(9):1079-85.
-
(2011)
Circulation
, vol.124
, Issue.9
, pp. 1079-1085
-
-
Falk, R.H.1
-
4
-
-
0035797855
-
Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts
-
Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation. 2001;104(14):1594-7.
-
(2001)
Circulation
, vol.104
, Issue.14
, pp. 1594-1597
-
-
Liao, R.1
Jain, M.2
Teller, P.3
Connors, L.H.4
Ngoy, S.5
Skinner, M.6
-
5
-
-
84882528609
-
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity
-
Guan J, Mishra S, Shi J, Plovie E, Qiu Y, Cao X, et al. Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol. 2013;108(5):378.
-
(2013)
Basic Res Cardiol
, vol.108
, Issue.5
, pp. 378
-
-
Guan, J.1
Mishra, S.2
Shi, J.3
Plovie, E.4
Qiu, Y.5
Cao, X.6
-
6
-
-
84879576449
-
Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish
-
Mishra S, Guan J, Plovie E, Seldin DC, Connors LH, Merlini G, et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol. 2013;305(1):H95-103.
-
(2013)
Am J Physiol Heart Circ Physiol
, vol.305
, Issue.1
-
-
Mishra, S.1
Guan, J.2
Plovie, E.3
Seldin, D.C.4
Connors, L.H.5
Merlini, G.6
-
7
-
-
33646597285
-
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL
-
Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006;107(10):3854-8.
-
(2006)
Blood
, vol.107
, Issue.10
, pp. 3854-3858
-
-
Palladini, G.1
Lavatelli, F.2
Russo, P.3
Perlini, S.4
Perfetti, V.5
Bosoni, T.6
-
8
-
-
4644336052
-
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
-
Dispenzieri A, Gertz M, Kyle R, Lacy M, Burritt M, Therneau T, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-7.
-
(2004)
J Clin Oncol
, vol.22
, Issue.18
, pp. 3751-3757
-
-
Dispenzieri, A.1
Gertz, M.2
Kyle, R.3
Lacy, M.4
Burritt, M.5
Therneau, T.6
-
9
-
-
84860643971
-
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
-
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989-95.
-
(2012)
J Clin Oncol
, vol.30
, Issue.9
, pp. 989-995
-
-
Kumar, S.1
Dispenzieri, A.2
Lacy, M.Q.3
Hayman, S.R.4
Buadi, F.K.5
Colby, C.6
-
10
-
-
78649759752
-
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: A multicenter phase 1/2 dose-escalation study
-
Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 2010;116(23):4777-82.
-
(2010)
Blood
, vol.116
, Issue.23
, pp. 4777-4782
-
-
Moreau, P.1
Jaccard, A.2
Benboubker, L.3
Royer, B.4
Leleu, X.5
Bridoux, F.6
-
11
-
-
84877063628
-
Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: Results of a phase II trial
-
Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica. 2013;98(5):789-92.
-
(2013)
Haematologica
, vol.98
, Issue.5
, pp. 789-792
-
-
Sanchorawala, V.1
Patel, J.M.2
Sloan, J.M.3
Shelton, A.C.4
Zeldis, J.B.5
Seldin, D.C.6
-
12
-
-
84879458198
-
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
-
Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420-7.
-
(2013)
Blood
, vol.121
, Issue.17
, pp. 3420-3427
-
-
Wechalekar, A.D.1
Schonland, S.O.2
Kastritis, E.3
Gillmore, J.D.4
Dimopoulos, M.A.5
Lane, T.6
-
13
-
-
84876420384
-
Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis
-
Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D, Leung N, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013;48(4):557-61.
-
(2013)
Bone Marrow Transplant
, vol.48
, Issue.4
, pp. 557-561
-
-
Gertz, M.A.1
Lacy, M.Q.2
Dispenzieri, A.3
Kumar, S.K.4
Dingli, D.5
Leung, N.6
-
14
-
-
84863011518
-
High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement
-
Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood. 2012;119(5):1117-22.
-
(2012)
Blood
, vol.119
, Issue.5
, pp. 1117-1122
-
-
Madan, S.1
Kumar, S.K.2
Dispenzieri, A.3
Lacy, M.Q.4
Hayman, S.R.5
Buadi, F.K.6
-
15
-
-
78650987230
-
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score
-
Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86(1):12-8.
-
(2011)
Mayo Clin Proc
, vol.86
, Issue.1
, pp. 12-18
-
-
Kumar, S.K.1
Gertz, M.A.2
Lacy, M.Q.3
Dingli, D.4
Hayman, S.R.5
Buadi, F.K.6
-
16
-
-
84860895856
-
CyBorD: Stellar response rates in AL amyloidosis
-
Merlini G. CyBorD: stellar response rates in AL amyloidosis. Blood. 2012;119(19):4343-5.
-
(2012)
Blood
, vol.119
, Issue.19
, pp. 4343-4345
-
-
Merlini, G.1
-
17
-
-
0038518441
-
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis
-
Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440-5.
-
(2003)
Circulation
, vol.107
, Issue.19
, pp. 2440-2445
-
-
Palladini, G.1
Campana, C.2
Klersy, C.3
Balduini, A.4
Vadacca, G.5
Perfetti, V.6
-
18
-
-
84884171906
-
Systemic light chain amyloidosis: An update for treating physicians
-
Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121(26):5124-30.
-
(2013)
Blood
, vol.121
, Issue.26
, pp. 5124-5130
-
-
Merlini, G.1
Wechalekar, A.D.2
Palladini, G.3
-
19
-
-
84860897399
-
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
-
Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387-90.
-
(2012)
Blood
, vol.119
, Issue.19
, pp. 4387-4390
-
-
Venner, C.P.1
Lane, T.2
Foard, D.3
Rannigan, L.4
Gibbs, S.D.5
Pinney, J.H.6
-
20
-
-
83255185724
-
Preclinical development of siRNA therapeutics for AL amyloidosis
-
Hovey BM, Ward JE, Soo Hoo P, O'Hara CJ, Connors LH, Seldin DC. Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther. 2011;18(12):1150-6.
-
(2011)
Gene Ther
, vol.18
, Issue.12
, pp. 1150-1156
-
-
Hovey, B.M.1
Ward, J.E.2
Soo, H.P.3
O'Hara, C.J.4
Connors, L.H.5
Seldin, D.C.6
-
21
-
-
78149282151
-
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
-
Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468(7320):93-7.
-
(2010)
Nature
, vol.468
, Issue.7320
, pp. 93-97
-
-
Bodin, K.1
Ellmerich, S.2
Kahan, M.C.3
Tennent, G.A.4
Loesch, A.5
Gilbertson, J.A.6
-
22
-
-
84055223035
-
Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis
-
Ward JE, Ren R, Toraldo G, Soohoo P, Guan J, O'Hara C, et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 2011;118(25):6610-7.
-
(2011)
Blood
, vol.118
, Issue.25
, pp. 6610-6617
-
-
Ward, J.E.1
Ren, R.2
Toraldo, G.3
Soohoo, P.4
Guan, J.5
O'Hara, C.6
-
23
-
-
77955227051
-
Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis
-
Mereles D, Buss SJ, Hardt SE, Hunstein W, Katus HA. Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol. 2010;99(8):483-90.
-
(2010)
Clin Res Cardiol
, vol.99
, Issue.8
, pp. 483-490
-
-
Mereles, D.1
Buss, S.J.2
Hardt, S.E.3
Hunstein, W.4
Katus, H.A.5
-
24
-
-
84876045920
-
Left ventricular device implantation for advanced cardiac amyloidosis
-
Swiecicki PL, Edwards BS, Kushwaha SS, Dispenzieri A, Park SJ, Gertz MA. Left ventricular device implantation for advanced cardiac amyloidosis. J Heart Lung Transplant. 2013;32(5):563-8.
-
(2013)
J Heart Lung Transplant
, vol.32
, Issue.5
, pp. 563-568
-
-
Swiecicki, P.L.1
Edwards, B.S.2
Kushwaha, S.S.3
Dispenzieri, A.4
Park, S.J.5
Gertz, M.A.6
-
25
-
-
78249290790
-
Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure
-
Dey BR, Chung SS, Spitzer TR, Zheng H, Macgillivray TE, Seldin DC, et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation. 2010;90(8):905-11.
-
(2010)
Transplantation
, vol.90
, Issue.8
, pp. 905-911
-
-
Dey, B.R.1
Chung, S.S.2
Spitzer, T.R.3
Zheng, H.4
Macgillivray, T.E.5
Seldin, D.C.6
-
26
-
-
54049148697
-
Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone
-
Lebovic D, Hoffman J, Levine BM, Hassoun H, Landau H, Goldsmith Y, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol. 2008;143(3):369-73.
-
(2008)
Br J Haematol
, vol.143
, Issue.3
, pp. 369-373
-
-
Lebovic, D.1
Hoffman, J.2
Levine, B.M.3
Hassoun, H.4
Landau, H.5
Goldsmith, Y.6
-
27
-
-
60749115105
-
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide
-
Palladini G, Russo P, Lavatelli F, Nuvolone M, Albertini R, Bosoni T, et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol. 2009;88(4):347-50.
-
(2009)
Ann Hematol
, vol.88
, Issue.4
, pp. 347-350
-
-
Palladini, G.1
Russo, P.2
Lavatelli, F.3
Nuvolone, M.4
Albertini, R.5
Bosoni, T.6
-
28
-
-
77956051099
-
Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement
-
Dietrich S, Schonland SO, Benner A, Bochtler T, Kristen AV, Beimler J, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood. 2010;116(4):522-8.
-
(2010)
Blood
, vol.116
, Issue.4
, pp. 522-528
-
-
Dietrich, S.1
Schonland, S.O.2
Benner, A.3
Bochtler, T.4
Kristen, A.V.5
Beimler, J.6
|